A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder

Canadian Journal of Psychiatry

Volumn 56, Issue 9, 2011, Pages 558-566

  Boschen, Mark J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Generalized anxiety disorder; Meta analysis; Pregabalin

Indexed keywords

BENZODIAZEPINE; BUSPIRONE; HYDROXYZINE; PLACEBO; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; GENERALIZED ANXIETY DISORDER; HUMAN; META ANALYSIS; SCORING SYSTEM;

EID: 80053436516     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371105600907     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Arlington (VA): American Psychiatric Press; 2000.
2. Barrera TL, Norton PJ. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord. 2009;23:1086-1090.
3. Stein MB, Heimberg RG. Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. J Affect Disord. 2004;79:161-166. (Pubitemid 38340539)
4. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146:317-325. (Pubitemid 351650592)
5. Jones GN, Ames SC, Jeffries SK, et al. Utilization of medical services and quality of life among low-income patients with generalized anxiety disorder attending primary care clinics. Int J Psychiatry Med. 2001;21:183-198. (Pubitemid 33049662)
6. Somers JM, Goldner EM, Waraich P, et al. Prevalence and incidence of anxiety disorders: a systematic review of the literature. Can J Psychiatry. 2006;51:100-113.
7. Boschen MJ. Publication trends in individual anxiety disorders: 1980-2005. J Anxiety Disord. 2008;22:570-575. (Pubitemid 351375355)
8. Boschen MJ, Neumann, DL, Waters AM. Relapse of successfully treated anxiety and fear: theoretical issues and recommendations for clinical practice. Aust N Z J Psychiatry. 2009;43:89-100.
9. Yonkers KA, Bruce SE, Dyck IR, et al. Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17:173-179. (Pubitemid 36644715)
10. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3:185-191. (Pubitemid 46864058)
11. Boschen MJ. Generalized anxiety disorder in adults: focus on pregabalin. CMI Psychiatry. 2011;4:17-35.
12. Bandelow D, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother. 2007;7:769-781. (Pubitemid 47037717)
13. Czuczwar SJ, Patsalos PM. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs. 2001;15:339-350. (Pubitemid 32487991)
14. Stahl S. Anticonvulsants as anxiolytics, part 2: pregabalin and gabapentin as α2δ ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:460-461.
15. Stahl S. Mechanism of action of α2δ ligands: voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry. 2004;65:1033-1034.
16. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75-82. (Pubitemid 46161838)
17. Pfizer Inc. Prescribing information-LYRICA (pregabalin). New York (NY): Pfizer; 2010.
18. Brockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Psychopharmacol. 2010;50:941-950.
19. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-249. (Pubitemid 36807791)
20. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160:533-540. (Pubitemid 41094262)
21. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022-1030. (Pubitemid 41248382)
22. Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, plaebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151-158. (Pubitemid 40395093)
23. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771-782. (Pubitemid 43946184)
24. Montgomery SA, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalized anxiety disorder. Br J Psychiatry. 2008;193:389-394.
25. Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a doubleblind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009;24:87-96.
26. Feltner D, Wittchen H-U, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23:18-28. (Pubitemid 350294866)
27. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacological treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21:864-872. (Pubitemid 350029180)
28. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
29. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat. 1981;6:107-128.
30. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
31. Kobak KA, Reynolds WM, Greist JH. Development and validation of a computer-administered version of the Hamilton Anxiety Scale. Psychol Assess. 1993;5:487-494.
32. Borenstein M, Hedges L, Higgins J, et al. Comprehensive metaanalysis (Version 2) [computer software]. Englewood (NJ): Biostat; 2005.
33. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat. 1998;2:Article2a.
34. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
35. Fountoulakis KN, Möller H-J. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol. 2010;27:1-8.
36. Horder J, Matthews P, Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol. 2010 June 22. Epub ahead of print.
37. Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull. 2005;131:785-795. (Pubitemid 41463587)